Frankfurt
16.07.26 | 15:25
0,478 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans | 1 | GlobeNewswire (USA) | ||
| 25.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.05.2026 | 567 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.05.2026
Aktien
1 GRS148003015 Ideal Holdings S.A.
2... ► Artikel lesen | |
| 22.05. | Arch Biopartners Inc: Arch Biopartners notes patient dosing in phase II trial | 1 | Stockwatch | ||
| 22.05. | Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial | 1 | GlobeNewswire (USA) | ||
| 30.04. | Arch Biopartners Inc: Arch Biopartners talks patient recruitment at RCH | 1 | Stockwatch | ||
| 11.04. | Arch Biopartners Inc: Arch Biopartners one-million-share private placement | 1 | Stockwatch | ||
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 02.04. | Arch Biopartners Inc: Arch Biopartners closes $600,000 private placement | 2 | Stockwatch | ||
| 02.04. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 30.03. | Arch Biopartners Inc: Arch Biopartners arranges $600,000 private placement | 2 | Stockwatch | ||
| 30.03. | Arch Biopartners Arranges Non-Brokered Private Placement | 3 | GlobeNewswire (USA) | ||
| 25.03. | Arch Biopartners Inc: Arch, Royal Columbian enter clinical trial deal | 1 | Stockwatch | ||
| 24.03. | Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | 2 | GlobeNewswire (USA) | ||
| 20.03. | Arch Biopartners Inc: Arch Biopartners begins dosing at 3rd CS-AKI trial site | 1 | Stockwatch | ||
| 20.03. | Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide | 1 | GlobeNewswire (USA) | ||
| 09.02. | Arch Biopartners Inc: Archlinks IL-32 to diabetic kidney inflammation | 1 | Stockwatch | ||
| 09.02. | Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease | 1 | GlobeNewswire (USA) | ||
| 05.11.25 | Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia | 248 | GlobeNewswire (Europe) | TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board ("REB")... ► Artikel lesen | |
| 17.09.25 | Arch Biopartners: Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) | 191 | GlobeNewswire (Europe) | Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated... ► Artikel lesen | |
| 06.08.25 | Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury | 191 | GlobeNewswire (Europe) | First patient successfully completes dosing at Toronto General HospitalSt. Michael's Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites... ► Artikel lesen | |
| 22.07.25 | Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) | 253 | GlobeNewswire (Europe) | TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled "Prevention... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 19,020 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,740 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,020 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| QIAGEN | 36,165 | 0,00 % | Märkte am Morgen: Öl, Applied Materials, Meta, Commerzbank, Telekom, Salzgitter, Südzucker, Qiagen | Die Bullen haben sich am deutschen Aktienmarkt zurückgemeldet. Der DAX legte gestern trotz einer kurzzeitigen Schwächephase zu. Am Ende lag er 0,89 Prozent höher bei 25.118 Punkten.An der Vortagen hatte... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,640 | 0,00 % | JPMorgan startet Coverage für Tango Therapeutics mit "Overweight" | ||
| APOGEE THERAPEUTICS | 134,08 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,380 | -0,04 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,83 | -0,12 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| TAYSHA GENE THERAPIES | 5,970 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| ANNEXON | 5,890 | 0,00 % | Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 37,940 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| NURIX THERAPEUTICS | 23,070 | 0,00 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| IMMUNOME | 22,200 | 0,00 % | Immunome Stock Up 32% in a Month: Here's What You Should Know | ||
| INHIBRX BIOSCIENCES | 89,07 | 0,00 % | Inhibrx Biosciences, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 69,50 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter |
ARCH BIOPARTNERS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,478 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.